menu
    • menu
    [{"orgOrder":0,"company":"SpliceBio","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"ABCA4 gene","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SpliceBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SpliceBio \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"SpliceBio \/ Ysios Capital"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SpliceBio","amount2":0.22,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.22,"dosageForm":"","sponsorNew":"SpliceBio \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"2","companyTruncated":"SpliceBio \/ Spark Therapeutics, Inc"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SB-007","moa":"","graph1":null,"graph2":null,"graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"SpliceBio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SpliceBio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SpliceBio

    Menu

    SpliceBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SB-007

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SpliceBio Receives FDA IND Clearance for Stargardt Disease Phase 1/2 Study

                            Details : SB-007 is a protein splicing dual AAV gene therapy that delivers the full-length ABCA4 gene. It is being evaluated for the treatment of stargardt disease.

                            Brand Name : SB-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 12, 2024

                            Lead Product(s) : SB-007

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Sponsor : Spark Therapeutics, Inc

                            Deal Size : $216.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retina...

                            Details : Under the agreement, Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 17, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Sponsor : Spark Therapeutics, Inc

                            Deal Size : $216.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed

                            SpliceBio

                            Spain arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Ysios Capital

                            Deal Size : $56.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            SpliceBio Raises EUR 50M in Oversubscribed Series A Financing to Advance Protein Splicing Platform and Expand ...

                            Details : The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Ysios Capital

                            Deal Size : $56.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth